United States - English - NLM (National Library of Medicine)

aim immunotech inc - interferon alfa-n3 (unii: 47bpr3v3mp) (interferon alfa-n3 - unii:47bpr3v3mp) - interferon alfa-n3 5000000 [arb'u] in 1 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 15 miu/ml - solution for injection - 18 miu - active: interferon alfa-2b 15 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 25 miu/ml - solution for injection - 30 miu - active: interferon alfa-2b 25 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 50 miu/ml - solution for injection - 60 miu - active: interferon alfa-2b 50 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml - solution for injection - 135 mcg/0.5ml - active: peginterferon alfa-2a 270 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate soln 10% polysorbate 80 sodium acetate trihydrate sodium chloride water for injection - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 135 µg/ml - solution for injection - 135 mcg/ml - active: peginterferon alfa-2a 135 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate 10% soln polysorbate 80 sodium acetate trihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - peginterferon alfa-2a 360 µg/ml - solution for injection - 180 mcg/0.5ml - active: peginterferon alfa-2a 360 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate soln 10% polysorbate 80 sodium acetate trihydrate sodium chloride water for injection - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 180 µg/ml - solution for injection - 180 mcg/ml - active: peginterferon alfa-2a 180 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate soln 10% polysorbate 80 sodium acetate trihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg;  ;   - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg;  ;   - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease